Search
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications.
Ethosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705ApprovedBimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.
Ornithine
go.drugbank.com/drugs/DB00129ApprovedInvestigationalNutraceuticalProduced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.
Caviar, unspecified
go.drugbank.com/drugs/DB14241ApprovedCaviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Elm
go.drugbank.com/drugs/DB14258ApprovedElm is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Patiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. … The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol.
Nitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.
Lobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes. … Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019.
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.